How to Determine Product Classification for Overseas Registration of POCT Products?

Product classification is the critical first step in overseas registration of POCT products, as it determines the registration pathway, technical documentation requirements, and approval timeline. Manufacturers must first verify whether the target country regulates the POCT product as a medical device, then classify it based on intended use, detection principle, sample type, and risk level. Under the GHWP framework (including China, ASEAN, Saudi Arabia, Brazil, and other member states), which aligns with GHTF classification principles, medical devices are grouped into Classes A, B, C, and D. POCT products typically fall into Class B or Class C, with some in Class D.

Classification assessment requires product descriptions, intended use statements, technical specifications, analytical performance data, and clinical evidence. Common risks include misclassifying a Class C product as Class B (leading to insufficient documentation), overlooking local classification rules (e.g., SFDA confirmation required in Saudi Arabia), and failing to separate reagent and instrument classifications. Manufacturers should first research the target country's regulations, compare classifications of already approved similar products, and submit a pre-classification consultation if needed. Classification directly affects subsequent quality system requirements (such as ISO 13485), local authorized representative responsibilities, and post-market surveillance, all of which influence registration timelines and costs.

Key Summary

For Chinese medical device manufacturers, a reliable approach is to first conduct a product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Registration in target markets simultaneously affects technical files, authorized representatives, importer cooperation, label language, quality system certification, and subsequent change management. If the project is approached only as 'submitting a set of documents,' companies often face corrections or rework in model coverage, evidence chain consistency, label claims, and certificate control.

Applicable Scenarios and Core Questions

Companies searching for 'how to determine product classification for overseas registration of POCT products' are typically looking for more than a conceptual explanation. They need to know whether existing documentation can support submission in the target market, whether a local agent or authorized representative is required, why timelines may be extended, and which issues could affect the launch plan. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or Southeast Asian, Middle Eastern, and Latin American markets simultaneously, answering the process for a single country is insufficient. A more valuable approach is to first create reusable versions of core technical documentation, quality system certificates, performance validation, clinical evidence, and labels/instructions for use, and then adapt them to the specific requirements of each country.

Registration Classification Logic

Step 1: Confirm Whether the Product Is a Medical Device

POCT products typically test human samples (such as blood, urine, or saliva) and are used for disease diagnosis or monitoring; most countries classify them as medical devices. However, some self-test products (e.g., pregnancy test strips) are classified as in-vitro diagnostic (IVD) devices in certain jurisdictions, and under the EU IVDR, they are considered medical devices.

Step 2: Determine Risk Class

Under the GHWP framework, devices are generally assigned to Class A (low risk), Class B (medium risk), Class C (higher risk), or Class D (high risk) based on the risk to patients and users. Common POCT classifications include:

• Class B: Screening or monitoring for non-serious conditions, such as blood glucose test strips or urine test strips.
• Class C: Diagnosis of serious conditions or making treatment decisions, such as cardiac troponin detection or infectious disease antigen tests (e.g., COVID-19 antigen).
• Class D: High-risk diseases, such as molecular tests for HIV or tuberculosis.

Step 3: Confirm the Registration Pathway

Different classifications correspond to different conformity assessment routes. For example, under the EU IVDR, Class B devices require a notified body to audit the technical documentation; Class C devices require a notified body review and involve performance evaluation; Class D devices additionally require reference laboratory consultation. ASEAN countries generally follow GHWP classification, and some allow self-declaration for Class B devices.

Step 4: Assess Reusability of Existing Documentation

If a company already holds an NMPA registration certificate, CE certificate, or FDA 510(k), some technical files can be reused, but local requirements must be considered, such as differences in applicable standards, language translation, and local clinical data requirements.

Documentation and Evidence

Typical documentation includes product description, model/specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system certificate, technical files, performance validation reports, risk management files, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance information.

The quality of documentation is not about quantity but consistency. Claims in the instructions for use, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings, and the registration application form must all support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for its intended use, not on how many documents are uploaded.

Common Mistakes

The most common mistake is treating a registration project as a simple document submission, without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Directly translating domestic NMPA files for submission without restructuring the evidence according to the target market pathway.
• Having excessive model/specification variants but insufficient coverage in test reports, clinical evidence, or labels.
• Selecting a local agent based solely on sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistencies among labels, instructions, promotional materials, and registration documents, leading to corrections or post-market compliance risks.
• Failing to plan for multi-country documentation reuse, resulting in repeated preparation in each country, inflating both cost and timeline.

Manufacturer Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation foundation, to avoid discovering critical evidence gaps after submission.

• Compile the target product list, model/specification matrix, and intended use statements.
• Review whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management documentation, clinical evaluation, and English instructions for use.
• Confirm the local agent or authorized representative's responsibilities, costs, certificate control, and exit mechanism.
• Establish a target country gap assessment table, indicating what needs to be re-tested, translated, notarized, or added as supplementary declarations.

AIMEILI Regulatory Interpretation and Business Impact

The most frequently misjudged aspect is the risk class of POCT products. Many companies assume that 'portable' implies low risk, but the actual focus is on the clinical significance of the detected biomarker. For example, cardiac troponin testing for acute myocardial infarction diagnosis is high risk and should be prepared as Class C. In the early stage of a project, we recommend a regulatory briefing or pre-classification consultation, especially when planning multi-country registration, to build a unified classification matrix and avoid duplicate work and corrections.

Reusable documentation includes risk management files and performance studies, but local standard differences must be considered (e.g., Brazil's ANVISA requires local clinical data). A local authorized representative not only handles classification communication but also holds control of the certificate and change processes; therefore, manufacturers must ensure the representative has adequate classification expertise. For multi-country registration, it is advisable to use the most stringent market as the baseline for preparing documents, then adjust to the requirements of other markets. Do not forget that classification may change upon post-market changes; for example, adding new indications may raise the risk class.

Frequently Asked Questions

Question 1: Our product is Class C under the EU IVDR; what would its classification be in Indonesia?

Indonesia follows the GHWP classification and generally aligns with the CE classification, but an official confirmation from the Indonesian Ministry of Health is required. We recommend submitting a classification request or referencing the registration status of similar products in Indonesia. Indonesia accepts certain CE documentation but may require English translations and a local agent.

Question 2: Should POCT instruments and reagents be registered separately or as a system?

Most countries require reagents and instruments to be registered separately, but system validation can be submitted together. For instance, the US FDA allows 510(k) submission as a system, while still listing them separately. Refer to the specific target country guidance for details.

Question 3: What should be done if a classification error is discovered?

If the error is identified before submission, proactively contact the regulatory authority to request reclassification or submit a pre-classification application. If the registration has already been submitted, it may be necessary to withdraw and reapply, causing delays and additional costs. We recommend having an experienced regulatory consultant review the classification before drafting the technical documentation.

Quality System and Evidence Consistency

From a regulatory review perspective, quality system documentation is not an isolated certificate. Regulators typically check consistency among the manufacturer's name, production address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate scope does not match the product under submission, or if the production address, model specifications, or instructions for use version differ from the test reports, the company may be asked for supplementary explanations even if extensive documentation has been provided.

Companies should create an evidence consistency checklist before submission, mapping each item—product name, model/specification, intended use, applicable standards, test report number, clinical evaluation conclusion, risk management version, label/IFU version, and quality system certificate—side by side. This basic step significantly reduces the likelihood of requests for correction, especially for projects involving multiple GHWP member states or multiple product families simultaneously.

Localization and Agent Responsibility

A target market registration project typically involves a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documents or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal notifications. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions, and authorization documents cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warning statements, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies already holding CE, FDA, NMPA, or other market documentation, the focus of localization is converting reusable evidence into the target country's acceptable submission structure, rather than writing a completely new set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean the end of compliance work. Companies must also manage certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance. Once a production address change, model expansion, instruction update, or agent change occurs, they may face a disconnect between the certificate and market sales.

AIMEILI recommends integrating this issue into an annual international registration plan: first, define target market priorities; then establish a reusable documentation package and a country-specific gap list; finally, schedule submission, correction, post-market maintenance, and renewal milestones. The value of this approach is not only improved registration efficiency in a single country, but also the creation of a replicable export compliance capability that reduces the cost of starting from scratch every time a company enters a new market.